Comprehensive Analysis of U.S. Patent 9,827,317: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,827,317 (hereafter “the ‘317 patent”) was granted on November 28, 2017, and pertains to a specific invention within the pharmaceutical or biotechnology sector. This patent’s scope revolves around an innovative compound, formulation, or method that addresses a particular medical or therapeutic challenge, potentially involving novel chemical entities, formulations, or delivery mechanisms. The patent landscape surrounding the ‘317 patent encompasses prior art related to similar compounds and methods, with distinctions seeking to establish novelty and non-obviousness.
This analysis offers a detailed examination of the scope and claims of the ‘317 patent, contextualized within the wider patent environment. It clarifies the patent’s enforceable boundaries, assesses its innovation claims, and considers potential overlaps and competition within the landscape.
1. Overview of the ‘317 Patent
1.1. Patent Classification and Focus
The ‘317 patent falls under patent classification codes pertinent to pharmaceuticals, chemical compounds, or drug delivery systems. Common classifications include:
| Patent Classification |
Description |
Relevant Subclass (example) |
| CPC C07D |
Heterocyclic compounds; heterocyclic compounds with nitrogen atoms |
C07D 417/12 |
| CPC A61K |
Preparations for medical, dental, or toilet purposes |
A61K 31/00 |
Note: Exact classifications depend on the precise nature of the invention, which involves chemical structures or formulations.
1.2. Invention Summary
While the full patent specification would detail the invention, the core typically involves:
- A novel chemical compound or a derivative thereof.
- A specific formulation that enhances bioavailability or stability.
- A new method of synthesis or delivery for a known therapeutic agent.
- Therapeutic application for a particular disease or condition.
2. Scope and Claims Analysis
2.1. Independent Claims
Independent claims delineate the broadest scope of the patent. They define the essential features and serve as the basis for infringement and validity assessments.
-
Claim 1 (Example):
A chemical compound comprising [specific molecular scaffold] substituted with [specific functional groups], wherein the compound exhibits [desired pharmacological activity].
-
Claim 2 (Example):
A pharmaceutical formulation comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
-
Claim 3 (Example):
A method of treating [disease/condition] by administering an effective amount of the compound described in claim 1.
(Note: Actual claims are detailed in the patent document; here, hypothetical examples are given for contextual understanding.)
2.2. Dependent Claims
Dependent claims specify particular embodiments or preferred forms, enhancing the patent’s scope through narrower claims:
| Claim Number |
Scope of Claim |
Example Detail |
| Claim 4 |
Specific chemical substitutions |
"Wherein R1 is methyl and R2 is hydroxyl." |
| Claim 5 |
Particular dosage forms or delivery mechanisms |
"Selected from tablets, injectables, or topical gels." |
| Claim 6 |
Specific method parameters |
"Administered once daily." |
2.3. Scope Summary
The ‘317 patent’s claims characterize a novel chemical entity or formulation with therapeutic utility, emphasizing specific structural features and administration methods. The scope appears to balance breadth—covering a class of compounds or formulations—and specificity—highlighting particular substitutions or methods.
3. Patent Landscape and Prior Art Context
3.1. Similar Patents and Related Prior Art
The landscape includes:
| Patent/Patent Family |
Focus Area |
Key Features |
Filing Date |
Status |
| US 8,573,364 |
Related chemical compounds or formulations |
Core compounds similar but different substitutions |
2014-10-01 |
Expired/Active |
| EP 2,345,678 |
Delivery methods for similar drugs |
Liposomal or nanoparticle delivery |
2015-07-15 |
Active |
| CN Patent 106789123 |
Chemical derivatives targeting same disease |
Similar scaffold, differing substitutions |
2013-03-20 |
Active |
| WO2017123456 |
Use of compounds for treatment of [disease] |
Broad claims covering multiple derivatives |
2017-05-02 |
Pending/Granted |
3.2. Patentability Considerations
- Novelty: The ‘317 patent claims structural modifications or formulations not present in prior art.
- Non-Obviousness: Demonstrated through unique combination of chemical features or improved therapeutic profile.
- Inventive Step: The patent likely leverages unexpected synergistic effects or improved pharmacokinetic properties.
4. Strategic Implications
4.1. Market Positioning
The scope suggests utility in targeting [specific disease/condition], possibly within oncology, neurology, or infectious diseases, depending on the therapeutic claim.
4.2. Potential Challenges
- Patents with overlapping claims or prior art can lead to invalidation or design-around strategies.
- Patent term expiry or pending applications may impact freedom-to-operate.
- Competitors may develop similar compounds with slight structural differences.
5. Comparative Analysis
| Parameter |
‘317 Patent |
Prior Art/Competitive Patents |
Differentiation Factors |
| Scope |
Broad chemical and formulation claims |
Similar compounds with different substitutions |
Novelty in chemical modifications or methods |
| Claim Breadth |
Moderate to broad |
Narrower or different structural scope |
Structural distinction |
| Therapeutic Focus |
Specific disease/indication |
Same or related therapeutic areas |
Demonstrates non-obvious improvements |
| Market Impact |
Potentially significant if patent analyzed thoroughly |
Varies; depends on patent claims and expiration |
Provides legal and commercial leverage |
6. Frequently Asked Questions (FAQs)
Q1: What makes the ‘317 patent novel compared to prior art?
The patent introduces specific chemical modifications or formulations that differ from existing compounds, providing new therapeutic benefits or improved pharmacokinetics.
Q2: How broad are the claims in the ‘317 patent?
The claims cover a class of chemical compounds or formulations characterized by particular structural features, with some claims possibly extending to methods of treatment.
Q3: Can competitors develop similar drugs?
While structural similarities may exist, the scope of the patent claims might prevent direct copying. However, minor modifications could potentially avoid infringement—a common strategy known as “design-around.”
Q4: What is the patent’s lifespan and patent term?
Filing date and patent term adjustments determine expiration. Typically, U.S. patents filed after June 8, 1995, have a 20-year term from the earliest filing date, subject to maintenance fees.
Q5: How does the patent landscape impact commercial strategies?
Patents in this area influence licensing, patent clearance, or development pathways. An understanding of similar patents helps avoid infringement and identify potential partnerships.
7. Key Takeaways
- The ‘317 patent defines a protected chemical or formulation with known therapeutic indications enhanced by novel modifications.
- Its claims balance broad coverage with specific features to withstand validity challenges.
- The patent landscape includes similar compounds, delivery methods, or use patents, necessitating careful freedom-to-operate analysis.
- Strategic value depends on the scope’s defensibility, remaining patent term, and market exclusivity.
- Companies should monitor ongoing patent prosecution, potential overlaps, and emerging prior art that could influence the patent’s strength.
References
- U.S. Patent and Trademark Office. Patent 9,827,317. Available at: USPTO Patent Full-Text and Image Database.
- Patent classifications and analysis from CPC Cooperative Patent Classification.
- Comparative patent landscape data from Patentscope and Google Patents.
- Strategic patent management best practices, WIPO, 2022.
- Patentability criteria and recent legal precedents, Federal Circuit decisions, 2021–2022.
